Oxler Private Wealth’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Oxler Private Wealth’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-100	Closed	-$9.62K	–	333
2022 Q3	$9.62K	Buy	+100	New	+$8.43K	0.01%	371
2021 Q1	–	Sell	-565	Closed	-$79K	–	221
2020 Q4	$79K	Buy	+565	New	+$72.4K	0.04%	143

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Oxler Private Wealth's XBI Position: Q4 2022 in Review

Oxler Private Wealth sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2022, closing a stake of 100 shares — an estimated $9.62K sold.

Oxler Private Wealth first reported a position in XBI in Q4 2020 and held it in 2 quarters. The position peaked at $79K in Q4 2020. 746 funds tracked by Wall St. Rank hold XBI as of Q4 2022.

Oxler Private Wealth reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2022 after selling out during the quarter.
Oxler Private Wealth sold 100 State Street SPDR S&P Biotech ETF shares in Q4 2022, an estimated $9.62K.
Oxler Private Wealth first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and held it in 2 quarters.
Oxler Private Wealth's State Street SPDR S&P Biotech ETF position peaked at $79K in Q4 2020.
746 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2022.

Based on Oxler Private Wealth's 13F filing for Q4 2022, filed 13 Feb 2023.